Monday 3rd February 2020, 4:30pm
The two companies bring together pioneering technology to increase the efficacy of gene therapeutics.
As of Monday 3rd February 2020, Synpromics will begin operating as AskBio, fully joining forces to accelerate their synthetic promoter technology into the clinic.
This combined expertise will transform the quality, efficacy and safety of gene therapy vectors, ultimately allowing for a wider scope of diseases treatable by AAV therapeutics.
Following Synpromics' acquisition last August, this marks further integration of European operations into AskBio, incorporating the latest scientific advances in order to develop new possibilities for genetic medicine and ultimately make history.
AskBio is rapidly advancing Synpromics' AAV promoter technology towards the clinic, enabling tissue selectivity with gene regulation capability. The rebrand to AskBio will continue this progress, integrating the companies' expertise more closely to drive the development of new cures.
Both teams of experts are excited to complete this transition and to apply their advanced technology in this new ecosystem, with Michael Roberts becoming Chief Technology Officer, AskBio Europe; David Venables now President, AskBio Europe; and Ken Macnamara becoming Chief Operating Officer, AskBio Europe.
European operations will continue to be based in Roslin Innovation Centre, on the outskirts of Edinburgh.
AskBio is now recruiting across both the US and European headquarters. Please contact AskBio if you would like to join this expanding team or have any questions about the company's research in AAV gene therapy.
Source: AskBio Europe